Investment Thesis
Werewolf Therapeutics is a pre-revenue biotech company with severe cash burn (-$60.3M annually) and less than one year of cash runway, combined with $32.1M in debt obligations it cannot service. Without demonstrated clinical success or near-term revenue generation, the fundamental risk substantially outweighs any speculative potential.
Strengths
- Maintains $57M cash position providing near-term operational runway
- Strong short-term liquidity with 1.62x current ratio
- Operating in pharmaceutical sector with potential for transformative therapies if pipeline advances
Risks
- Pre-revenue stage with no commercialized products creates existential uncertainty
- Critical cash runway of less than 12 months at current $60.3M annual burn rate
- Unable to service $32.1M debt from operations with -11.5x interest coverage ratio
- Negative returns (ROE -245%, ROA -87.6%) indicate significant ongoing value destruction
- Significant financial distress signals requiring near-term capital raise or liquidity event
Key Metrics to Watch
- Monthly cash burn rate and updated runway timeline
- Clinical trial milestones and regulatory pathway progress
- Capital raise activities and debt restructuring announcements
Financial Metrics
Revenue
N/A
Net Income
-60.8M
EPS (Diluted)
$-1.33
Free Cash Flow
-60.3M
Total Assets
69.4M
Cash
57.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-245.2%
ROA
-87.6%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.62x
Quick Ratio
1.62x
Debt/Equity
1.29x
Debt/Assets
64.3%
Interest Coverage
-11.50x
Long-term Debt
32.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-11T07:24:31.680828 |
Data as of: 2025-12-31 |
Powered by Claude AI